Supplement evidence

011 / 575Vitamin

Vitamin E

View my plan →

The short answer

Treating rare deficiency caused by specific fat-malabsorption or genetic disorders.

Evidence and scope: Common claim not supported
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: The USPSTF recommends against vitamin E for preventing cardiovascular disease or cancer.
Before deciding: High doses can increase bleeding risk and interact with anticoagulants.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Meeting usual needs15 mg/day alpha-tocopherol

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat-soluble / lipid-based

Fat-soluble or lipid-based. Absorption generally improves with a meal containing fat.

How it is commonly taken

Take with a meal containing fat.

Do not combine casually

High-dose supplements can increase bleeding risk with anticoagulants and have not shown general prevention benefit.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

5research papers in this ledger

9unique primary studies represented

107,772unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2022

Does not support the tested claimPMID 35727272

Vitamin, mineral, and multivitamin supplementation for primary prevention of cardiovascular disease and cancer

Vitamin E showed no benefit for all-cause mortality, cardiovascular events, or cancer. The broader review also identified hemorrhagic-stroke harm, so routine preventive use is not supported.

Published: 2022n=107,772 participants9 primary studies represented

Study design and methods

Design: Systematic evidence review for the U.S. Preventive Services Task Force
Population: 107,772 participants across nine vitamin E mortality trials, with overlapping cardiovascular and cancer trial sets
Intervention: Vitamin E alone or with selected co-supplements versus placebo or no supplement
Outcome: All-cause mortality, cardiovascular events, cancer, and serious harms

Open research record ↗

2011

Safety signalPMID 21990298 · NCT00006392

Vitamin E and the risk of prostate cancer: SELECT

Vitamin E alone increased prostate cancer risk by 17% relative to placebo and did not prevent cancer. This trial is represented in the broader prevention review and is displayed separately as a major harm signal.

Published: 2011Duration: Planned 7–12 years with extended follow-upn=35,533 participants

Study design and methods

Design: Large randomized, double-blind, placebo-controlled factorial trial
Population: 35,533 relatively healthy men in the United States, Canada, and Puerto Rico
Intervention: Synthetic vitamin E 400 IU/day, selenium, both, or placebo
Outcome: Prostate cancer incidence

Funding or conflict note: The trial was funded by U.S. public agencies; the harm signal emerged with longer follow-up.

Open research record ↗

2010

Safety signalPMID 21051774

Effects of vitamin E on stroke subtypes

Total stroke did not change; ischemic stroke fell 10% while hemorrhagic stroke rose 22%. The tradeoff and greater severity of hemorrhagic stroke argue against indiscriminate use, especially with bleeding risks.

Published: 2010n=118,765 participants9 primary studies represented

Study design and methods

Design: Systematic review and meta-analysis of nine randomized trials
Population: 118,765 adults across primary and secondary prevention trials
Intervention: Vitamin E supplementation versus placebo for at least one year
Outcome: Total, ischemic, and hemorrhagic stroke

Funding or conflict note: The trials overlap the broader prevention review, so this outcome-specific synthesis is excluded from aggregate totals.

Open research record ↗

2005

Safety signalPMID 15769967

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: HOPE-TOO

Vitamin E did not prevent cancer or major cardiovascular events and increased heart failure and heart-failure hospitalization. This trial is already represented in the broader prevention review.

Published: 2005Duration: Median 7 yearsn=9,541 participants

Study design and methods

Design: Extended randomized, double-blind, placebo-controlled international trial
Population: 9,541 adults aged 55 or older with vascular disease or diabetes in the original HOPE cohort
Intervention: Natural-source vitamin E 400 IU/day or placebo
Outcome: Cancer, major cardiovascular events, heart failure, and hospitalization

Open research record ↗

2005

Does not support the tested claimPMID 15998891

Vitamin E in the primary prevention of cardiovascular disease and cancer: Women's Health Study

Vitamin E did not reduce overall major cardiovascular events, cancer, or total mortality. Cardiovascular death was lower as a secondary component, but the overall prevention endpoints were null and do not support routine use.

Published: 2005Duration: Mean 10.1 yearsn=39,876 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled factorial trial
Population: 39,876 apparently healthy U.S. women aged 45 or older
Intervention: Natural-source vitamin E 600 IU every other day or placebo
Outcome: Major cardiovascular events, invasive cancer, and mortality

Funding or conflict note: Funded by the U.S. National Cancer Institute and National Heart, Lung, and Blood Institute; overlaps the broader prevention review.

Open research record ↗

Unscreened discovery appendix—not evidence3,860 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewU.S. Preventive Services Task Force Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.